Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 31 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/17/2008 First Published: 8/19/2005


1.		Phase III Randomized Study of Neoadjuvant Induction Therapy Comprising Doxorubicin, Cisplatin, and High-Dose Methotrexate (MAP) Followed by Surgery and Adjuvant Maintenance Therapy Comprising MAP Alone Versus MAP and PEG-Interferon Alfa-2b OR MAP Combined With Ifosfamide and Etoposide in Patients With Resectable High-Grade Osteosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				5 to 40 at diagnostic biopsy				NCI				COG-AOST0331 AOST0331, NCT00134030, ISRCTN67613327, EU-20530, MRC-EURAMOS1, MRC-BO08, EUDRACT-2004-000242-20

Last Modified: 10/21/2008 First Published: 7/14/2008


2.		Phase III Randomized Study of Sodium Thiosulfate in Preventing Ototoxicity in Young Patients Receiving Cisplatin-Based Chemotherapy for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, or Osteosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				1 to 18				NCI				COG-ACCL0431 COG-ACCL0431, ACCL0431, NCT00716976


3.		A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				30 and under				NCI, Other				OS2008 NCT00667342


4.		Deforolimus in Treatment of Sarcoma - SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				13 and over				Pharmaceutical / Industry				AP23573-07-302 NCT00538239


5.		Inhalation SLIT Cisplatin for the Treatment of Osteosarcoma Metastatic to the Lung

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				13 to 50				Pharmaceutical / Industry				TR02-2421 NCT00102531


6.		Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				10 and over				Pharmaceutical / Industry				A4021020 NCT00560235

Last Modified: 10/11/2007 First Published: 5/1/1999


7.		Phase II Study of Nonmyeloblative Allogeneic Peripheral Blood Stem Cell Transplantation and Donor Lymphocyte Infusions in Patients With Refractory Metastatic Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				10 to 80				NHLBI				NHLBI-99-H-0064 NCT00003839

Last Modified: 6/11/2008 First Published: 7/26/2003


8.		Phase II Study of Aerosolized Sargramostim (GM-CSF) in Patients With First Pulmonary Recurrence of Osteosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				39 and under				NCI				COG-AOST0221 AOST0221, NCT00066365

Last Modified: 6/1/2006 First Published: 10/21/2005


9.		Phase II Study of High-Dose Samarium Sm 153 Lexidronam Pentasodium and Autologous Peripheral Blood Stem Cell Transplantation Followed By External-Beam Radiotherapy in Patients With Recurrent or Refractory, Metastatic, or Unresectable Osteosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				13 to 50				NCI				JHOC-J0347 JHOC-03090802, NCT00245011

Last Modified: 5/9/2008 First Published: 7/23/2006


10.		Phase II Pilot Study of Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Young Patients With Relapsed or Progressive Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				21 and under				Other				DFCI-04343 NCT00357500

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute